eBioMedicine
The US Centers for Disease Control and Prevention estimates between 2.8% and 4.4% of adults in the USA are currently living with post-acute sequelae of COVID-19 (PASC; or long COVID) and that between 1.7% and 2.9% of US adults face substantial limitations in day-to-day activities due to PASC. Yet, despite hundreds of registered interventional trials aimed at addressing PASC, as of May, 2026, we still lack approved and broadly effective disease-modifying therapies for this debilitating condition.